Literature DB >> 16034086

T cell tolerance induced by cross-reactive TCR ligands can be broken by superagonist resulting in anti-inflammatory T cell cytokine production.

Zsolt Illés1, Hanspeter Waldner, Jayagopala Reddy, Estelle Bettelli, Lindsay B Nicholson, Vijay K Kuchroo.   

Abstract

Cross-reactive activation of potentially autoreactive T cells by high-affinity nonself ligands may be important in breaking self-tolerance in autoimmunity. In a mouse transgenic for a cross-reactive TCR, we have previously shown that a hyper-stimulating altered peptide ligand, L144, induced unresponsiveness to the self peptide, proteolipid protein 139-151. In this study, we demonstrate that a superagonist ligand can break T cell tolerance induced by the lower affinity cognate Ag. T cells tolerant to the cognate ligand, Q144, responded to superagonist, L144, by proliferation and the production of mainly IL-4 and IL-10 in vitro. In contrast, T cells that were tolerized to the superagonist were unable to respond to any peptide that cross-reacted with the transgenic TCR. Low-dose immunization with the superagonist L144 was able to break tolerance to the cognate ligand in vivo and resulted in a blunted proliferative response with production of Th2 cytokines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034086     DOI: 10.4049/jimmunol.175.3.1491

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells.

Authors:  Lizette M Cortes; Dody Avichezer; Phyllis B Silver; Dror Luger; Mary J Mattapallil; Chi-Chao Chan; Rachel R Caspi
Journal:  J Leukoc Biol       Date:  2008-05-21       Impact factor: 4.962

2.  Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients.

Authors:  Annie Boucher; Marc Desforges; Pierre Duquette; Pierre J Talbot
Journal:  Clin Immunol       Date:  2007-04-19       Impact factor: 3.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.